ADMA Biologics Inc (ADMA)
21.30
-0.07
(-0.33%)
USD |
NASDAQ |
Nov 21, 16:00
21.29
-0.01
(-0.05%)
After-Hours: 20:00
ADMA Biologics Revenue (Quarterly): 119.84M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 119.84M |
| June 30, 2024 | 107.19M |
| March 31, 2024 | 81.88M |
| December 31, 2023 | 73.90M |
| September 30, 2023 | 67.28M |
| June 30, 2023 | 60.12M |
| March 31, 2023 | 56.91M |
| December 31, 2022 | 49.98M |
| September 30, 2022 | 41.09M |
| June 30, 2022 | 33.90M |
| March 31, 2022 | 29.10M |
| December 31, 2021 | 26.38M |
| September 30, 2021 | 20.68M |
| June 30, 2021 | 17.83M |
| March 31, 2021 | 16.05M |
| December 31, 2020 | 13.96M |
| September 30, 2020 | 10.28M |
| June 30, 2020 | 7.788M |
| March 31, 2020 | 10.20M |
| December 31, 2019 | 12.04M |
| September 30, 2019 | 7.222M |
| June 30, 2019 | 6.561M |
| March 31, 2019 | 3.529M |
| December 31, 2018 | 4.056M |
| September 30, 2018 | 4.230M |
| Date | Value |
|---|---|
| June 30, 2018 | 4.657M |
| March 31, 2018 | 4.042M |
| December 31, 2017 | 12.00M |
| September 30, 2017 | 4.729M |
| June 30, 2017 | 3.399M |
| March 31, 2017 | 2.629M |
| December 31, 2016 | 3.328M |
| September 30, 2016 | 2.938M |
| June 30, 2016 | 2.272M |
| March 31, 2016 | 2.124M |
| December 31, 2015 | 2.512M |
| September 30, 2015 | 1.852M |
| June 30, 2015 | 1.310M |
| March 31, 2015 | 1.503M |
| December 31, 2014 | 1.489M |
| September 30, 2014 | 1.366M |
| June 30, 2014 | 1.500M |
| March 31, 2014 | 1.561M |
| December 31, 2013 | 0.424M |
| September 30, 2013 | 1.107M |
| June 30, 2013 | 0.7433M |
| March 31, 2013 | 0.7929M |
| December 31, 2012 | 0.5233M |
| September 30, 2012 | 0.3603M |
| June 30, 2012 | 0.2301M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
7.788M
Minimum
Jun 2020
119.84M
Maximum
Sep 2024
42.82M
Average
31.50M
Median
Revenue (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 182.55M |
| Madrigal Pharmaceuticals Inc | 62.18M |
| Assembly Biosciences Inc | 6.845M |
| TG Therapeutics Inc | 83.88M |
| Krystal Biotech Inc | 83.84M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 35.91M |
| Total Expenses (Quarterly) | 80.20M |
| EPS Diluted (Quarterly) | 0.15 |
| Enterprise Value | 5.050B |
| Gross Profit Margin (Quarterly) | 49.78% |
| Profit Margin (Quarterly) | 29.96% |
| Earnings Yield | 1.31% |
| Operating Earnings Yield | 2.27% |
| Normalized Earnings Yield | 1.315 |